Motley Fool  Jul 17  Comment 
Does this analyst make a good case? Or is it just more noise from Wall Street?
DailyFinance  Jul 16  Comment 
Piper Jaffray (NYSE:PJC) announced today that it will release its 2014 second quarter results prior to the opening of the market on Thursday, July 24, 2014. The company will also hold a conference call to review the...
Motley Fool  Jul 8  Comment 
Piper Jaffray argues that optimism might be a good investment strategy in its upgrading of Guess.
Benzinga  Jul 8  Comment 
Shares of Guess (NYSE: GES) gained over five percent on Tuesday after Piper Jaffay analyst Erinn Murphy upgraded Guess from Neutral to Overweight following meetings in Italy last week. After her discussions with apparel and accessories...
Benzinga  Jul 7  Comment 
In a report released Monday, Piper Jaffray analyst Michael Olson upgraded King Digital Entertainment (NYSE: KING) to Overweight, while increasing its price target from $19 to $28 per share. Olson believes King's second quarter results holds...
Benzinga  Jul 3  Comment 
In a note released Thursday, Piper Jaffray analyst Michael Olson said Netflix (NASDAQ: NFLX) has a "significant lead" in content compared to rivals Hulu and Amazon. According to his analysis, Netflix has widened the gap in movies and has an...
Motley Fool  Jun 30  Comment 
GW Pharmaceuticals explodes higher after receiving positive commentary from Wall Street. Can shares actually head even higher?
Benzinga  Jun 30  Comment 
In a report released Monday, Piper Jaffray analyst Gene Munster upgraded Yahoo (NASDAQ: YHOO) from Neutral to Overweight and raised the firm's price target by 16 percent, from $37 to $43 per share. Munster states that Yahoo is currently...
Benzinga  Jun 30  Comment 
In a note released Monday morning, Piper Jaffray made a big raise to the price target of GW Pharmaceuticals (NASDAQ: GWPH) from $97 to $147, citing the potential of GW's Epidiolex to treat epilepsy. The analysts at Piper Jaffray say that the...
Jutia Group  Jun 26  Comment 
The Life Sciences Report: How long have you followed Inovio Pharmaceuticals Inc. (INO:NYSE.MKT)? Charles Duncan: I've covered Inovio Pharmaceuticals for several years. We initiated on it at Piper Jaffray, along with the rest of our coverage, a...

You may also be interested in articles related to Piper Jaffray Companies (PJC):

You have more usfuel info than the British had colonies pre-WWII.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki